Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nonalcoholic steatohepatitis.

B A Neuschwander-Tetri1

  • 1Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, Missouri 63110, USA.

Clinics in Liver Disease
|November 25, 2004
PubMed
Summary

Non-alcoholic steatohepatitis (NASH) is a serious chronic liver disease. Early diagnosis and weight management are crucial for obese patients, while others require ongoing monitoring and potential liver transplantation for advanced stages.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis.

Alimentary pharmacology & therapeutics·2016
Same author

Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis.

Alimentary pharmacology & therapeutics·2013
Same author

Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.

Gut·2008
Same author

Unexplained CK elevations in patients with nonalcoholic steatohepatitis.

Liver international : official journal of the International Association for the Study of the Liver·2006
Same author

A resistance movement in NASH.

The American journal of gastroenterology·2001
Same author

Betaine: an old therapy for a new scourge.

The American journal of gastroenterology·2001

Area of Science:

  • Hepatology
  • Gastroenterology
  • Internal Medicine

Background:

  • Non-alcoholic steatohepatitis (NASH) is a significant and increasingly recognized chronic liver disease.
  • Diagnosis relies on biopsy findings in patients with a history of abstinence, showing similarities to alcoholic hepatitis.
  • Obesity is a primary risk factor, though NASH can affect non-obese individuals.

Purpose of the Study:

  • To highlight the importance of recognizing NASH due to its progressive nature.
  • To emphasize the role of liver biopsy in evaluating unexplained liver abnormalities.
  • To discuss current diagnostic and therapeutic strategies for NASH.

Main Methods:

  • Diagnostic criteria involving biopsy findings and patient history (abstinence).
  • Identification of risk factors, including obesity.
  • Assessment of disease progression to fibrosis, cirrhosis, and end-stage liver disease.

Main Results:

  • NASH can progress to cirrhosis and liver failure in 20% to 40% of patients.
  • Weight reduction is the primary treatment for obese patients.
  • Non-obese patients currently have limited treatment options beyond observation.

Conclusions:

  • Prompt recognition and diagnosis of NASH are critical for patient outcomes.
  • Liver biopsy remains essential for diagnosing NASH and evaluating disease severity.
  • Further research into NASH pathophysiology is needed to develop targeted diagnostic tests and effective therapies.
  • Liver transplantation is an option for patients with decompensated cirrhosis, excluding those with contraindications.

Related Experiment Videos